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Acute heart failure in sub-Saharan 
Africa
Acute heart failure (AHF) is a common mechanism of death in 
sub-Saharan Africa (SSA).[1] The most common cause is untreated 
hypertension, which as elsewhere in the world, including Europe, the 
USA, India, China, Africa and South Africa (SA), has a dire prognosis 
associated with high mortality.
The treatment of this common condition in SSA is not well 
documented. However, it is likely that, as in North America, loop 
diuretics are usually tried early in the course of therapy. In North 
America, patients with decompensated AHF are given loop diuretics 
as an essential component of therapy,[2] yet there are few randomised 
prospective data to guide their use. There were no significant 
differences in patients’ global assessment of symptoms or in the 
change in renal function when diuretic therapy was administered by 
bolus as opposed to continuous infusion, or at a high dose as opposed 
to a low dose. 
Hypertension as a cause of 
heart failure
Hypertension is common in Africa, as is heart failure.[1] Establishing 
the cause of AHF would enable specific therapy to be started as a 
matter of urgency. For example, a patient with hypertensive AHF 
needs urgent intravenous therapy to reduce the blood pressure. 
Besides the typical clinical presentation of cardiomegaly and often 
atrial fibrillation, AHF may first manifest itself indirectly as left 
ventricular systolic dysfunction, especially in the elderly and in 
people with diabetes.[3]
Analysis of gender differences in AHF shows that modifiable 
lifestyle risk factors are prominent in men, while women more 
commonly have rheumatic heart disease and nutritional deficiencies, 
as shown in the Sub-Saharan Africa Survey of Heart Failure (THESUS-
HF) study on 1 006 subjects.[4] This study found that the causes of 
AHF in Africa were typically non-ischaemic, with hypertension a 
prominent cause. In contrast, in North America and in European 
countries the typical cause of AHF is ischaemic heart disease rather 
than hypertension.[5]
Conclusion
With regard to the treatment of AHF, there are both clinical and 
research messages. Neglected hypertension, although relatively easy 
to treat, is a frequent source of AHF. The problem in rural African 
communities in SSA is that hypertension is seldom diagnosed and 
appropriate therapy is seldom instituted, so that a crisis is likely to 
occur after years of neglect. Ideally, the populations of sub-Saharan 
countries such as Nigeria, Kenya, Tanzania, SA and Mozambique 
should have much better access to mobile clinics that can reach the 
non-urban population. 
The clinical message is that not only are the complications 
of significant hypertension susceptible to therapy, but preventive 
measures such as salt reduction, mobile clinics and workplace blood 
pressure measurements would help to counter the disease earlier. 
The research message is that laboratory research should focus 
on preventive therapy directed at preservation of the threatened 
myocardium, including much wider use of angiotensin-converting 
enzyme inhibitors or even novel metabolic therapy such as reducing 
the elevated cardiotoxic blood free fatty acids. 
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